Product Description
Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Gadoteridol)
Mechanisms of Action: Contrast Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Colombia | Croatia | Czech | Denmark | Estonia | Finland | France | Germany | Greece | Hungary | India | Ireland | Italy | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Kingdom | United States | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location: LEVERKUSEN 2M D-51368
Company CEO: Werner Baumann
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Bulgaria, Canada, China, Czech Republic, France, Germany, Hungary, Italy, Japan, Korea, Poland, South Korea, Sweden, Taiwan, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Brain Diseases|Other|Spinal Cord Diseases|Spinal Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Quanti OBR | P3 |
Completed |
Other |
2024-05-31 |
66% |
| Quanti OBR | P3 |
Completed |
Other |
2024-05-31 |
66% |
| Quanti OBR | P3 |
Completed |
Other |
2024-05-31 |
66% |
| Quanti OBR | P3 |
Completed |
Other |
2024-05-31 |
66% |
| Quanti CNS | P3 |
Completed |
Other |
2024-05-30 |
66% |
| Quanti CNS | P3 |
Completed |
Other |
2024-05-30 |
66% |
| Quanti CNS | P3 |
Completed |
Other |
2024-05-30 |
66% |
| Quanti CNS | P3 |
Completed |
Other |
2024-05-30 |
66% |
| CTR20232190 | P3 |
Recruiting |
Spinal Cord Diseases|Spinal Diseases|Brain Diseases |
None |
|
| CTR20232191 | P3 |
Recruiting |
Spinal Diseases|Brain Diseases|Spinal Cord Diseases |
None |